Sara Barrington, CEO Verici Dx discusses the significant market opportunity & upcoming milestones

Sara Barrington, CEO of immuno-diagnostics development company Verici Dx #VRCI discusses the significant market opportunity and upcoming milestones.

Verici Dx is an immuno-diagnostics development company, initially focused on the kidney transplantation market. The Company’s kidney transplant assays use advanced next-generation sequencing that may define a personalised, risk-profile of each patient over the course of their transplant journey, as well as may detect injury in advance of currently available clinical tests.